ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2019
Last Updated on 02 May 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Ezetimibe 10 mg tablet for treating primary (heterozygous familial and non-familial) hypercholesterolaemia in adults as:
    • Add-on therapy to statins when the cholesterol concentration therapeutic target is not achieved at the maximum tolerated statin dose; or
    • Monotherapy as an alternative to statins for adults who are intolerant of, or contraindicated to, statin therapy.
Intolerance to statin therapy is defined as the occurrence of clinically significant adverse effects that are an unacceptable risk to the patient.

Subsidy status
Ezetimibe 10 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy does not apply to ezetimibe/simvastatin 10/10 mg or 10/20 mg tablets.

Ezetimibe and ezetimibe_simvastatin for treating primary hypercholesterolaemia (2 May 2019) Ezetimibe Plain English Summary (2 May 2019)